JP2010535508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535508A5 JP2010535508A5 JP2010520314A JP2010520314A JP2010535508A5 JP 2010535508 A5 JP2010535508 A5 JP 2010535508A5 JP 2010520314 A JP2010520314 A JP 2010520314A JP 2010520314 A JP2010520314 A JP 2010520314A JP 2010535508 A5 JP2010535508 A5 JP 2010535508A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- composition
- seq
- kinase
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108091000080 Phosphotransferase Proteins 0.000 claims 8
- 102000020233 phosphotransferase Human genes 0.000 claims 8
- 229940043355 kinase inhibitor Drugs 0.000 claims 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 6
- 230000037396 body weight Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008196 pharmacological composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96394107P | 2007-08-07 | 2007-08-07 | |
| US60/963,941 | 2007-08-07 | ||
| US99497007P | 2007-09-24 | 2007-09-24 | |
| US60/994,970 | 2007-09-24 | ||
| PCT/US2008/072525 WO2009021137A2 (en) | 2007-08-07 | 2008-08-07 | Kinase inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535508A JP2010535508A (ja) | 2010-11-25 |
| JP2010535508A5 true JP2010535508A5 (https=) | 2014-05-15 |
| JP5703466B2 JP5703466B2 (ja) | 2015-04-22 |
Family
ID=40342047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520314A Expired - Fee Related JP5703466B2 (ja) | 2007-08-07 | 2008-08-07 | キナーゼ阻害薬およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8741849B2 (https=) |
| EP (1) | EP2185698B1 (https=) |
| JP (1) | JP5703466B2 (https=) |
| DK (1) | DK2185698T3 (https=) |
| ES (1) | ES2547229T3 (https=) |
| WO (1) | WO2009021137A2 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007342674B2 (en) | 2007-01-10 | 2013-09-19 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| US20080293640A1 (en) * | 2007-01-10 | 2008-11-27 | Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| JP5703466B2 (ja) | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| CN102256613B (zh) * | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| AU2013202108B2 (en) * | 2008-12-10 | 2015-12-24 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| CA2744104C (en) | 2008-12-10 | 2017-07-18 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| US20130115256A1 (en) * | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| US9540443B2 (en) | 2011-01-26 | 2017-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| BR112013026313A8 (pt) | 2011-04-12 | 2018-01-30 | Moerae Matrix Inc | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular |
| CN102949722A (zh) * | 2011-08-26 | 2013-03-06 | 中国医学科学院放射医学研究所 | 基于p38抑制剂和细胞生长因子的新颖药物组合物 |
| EP2771069A4 (en) | 2011-10-27 | 2015-08-26 | Mayo Foundation | INHIBITION OF G-PROTEIN-COUPLED RECEPTOR-6-KINASE POLYPEPTIDE |
| WO2013067050A1 (en) * | 2011-10-31 | 2013-05-10 | University Of Utah Research Foundation | Genetic alterations in glioblastoma |
| WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| CA2868302A1 (en) | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| US20140072613A1 (en) * | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
| WO2014160364A1 (en) * | 2013-03-13 | 2014-10-02 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
| AU2014250830A1 (en) | 2013-04-11 | 2015-11-12 | Vanderbilt University | Polyplexes |
| GB201314610D0 (en) * | 2013-08-15 | 2013-10-02 | Blueberry Therapeutics Ltd | Compounds and their uses |
| US9644037B2 (en) | 2013-10-18 | 2017-05-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use |
| CN103739678B (zh) * | 2013-12-31 | 2015-09-02 | 刘培臣 | 抑制粘附斑激酶多肽及其应用 |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| EP3134399A4 (en) | 2014-04-21 | 2017-12-27 | Mayo Foundation for Medical Education and Research | Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides |
| CN113975386A (zh) | 2014-05-23 | 2022-01-28 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
| AU2015300966A1 (en) * | 2014-08-08 | 2017-02-16 | Janssen Pharmaceutica Nv | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| WO2016032882A1 (en) * | 2014-08-25 | 2016-03-03 | Stc.Unm | Inhibition of mk2 in the treatment of cancer |
| CN107106650A (zh) | 2014-11-17 | 2017-08-29 | 莫伊莱麦屈克斯公司 | 用于预防或治疗表征为异常的成纤维细胞增殖和细胞外基质沉积的疾病、状况或过程的组合物和方法 |
| EP3242886A4 (en) | 2015-01-08 | 2018-08-29 | Moerae Matrix, Inc., | Formulation of mk2 inhibitor peptides |
| JP2018512401A (ja) * | 2015-03-12 | 2018-05-17 | モイライ マトリックス インコーポレイテッド | Ｍｋ２阻害剤ペプチド含有組成物を用いた非小細胞肺癌の治療を目的とするその使用 |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| WO2017147526A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US11213857B2 (en) | 2017-06-06 | 2022-01-04 | Derrick Corporation | Method and apparatus for screening |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| JP7644000B2 (ja) * | 2018-05-15 | 2025-03-11 | インテルク ペプチド セラピューティクス リミテッド | 活性化剤 |
| JP7386852B2 (ja) * | 2018-05-15 | 2023-11-27 | インテルク ペプチド セラピューティクス リミテッド | ペプチド活性化剤 |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| WO2020053812A1 (en) * | 2018-09-12 | 2020-03-19 | Purdue Research Foundation | Alkynyl nicotinamide compounds as kinase inhibitors |
| CA3126143A1 (en) * | 2019-01-11 | 2020-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Pi4-kinase inhibitors with anti-cancer activity |
| US12415788B2 (en) | 2019-03-21 | 2025-09-16 | The Board Of Trustees Of The Leland Stanford Junior University | PI4-kinase inhibitors and methods of using the same |
| WO2021097407A2 (en) * | 2019-11-15 | 2021-05-20 | Regents Of The University Of Colorado, A Body Corporate | Novel peptide compositions and methods of treating neurological injury |
| CN114605497B (zh) * | 2021-02-10 | 2023-04-28 | 北京欣安诚科技有限公司 | 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途 |
| CN115976033B (zh) * | 2022-12-14 | 2024-05-17 | 西南大学 | 瓜实蝇tssk1和tssk3基因及其应用 |
| WO2025151669A1 (en) * | 2024-01-10 | 2025-07-17 | President And Fellows Of Harvard College | Clk2 inhibition as a radiation countermeasure |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| GB2129691B (en) | 1982-10-08 | 1987-08-05 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| AU591152B2 (en) | 1985-07-30 | 1989-11-30 | Glaxo Group Limited | Devices for administering medicaments to patients |
| US5175144A (en) | 1988-11-29 | 1992-12-29 | The Johns Hopkins University | Method of retarding the progression of chronic renal failure |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| WO1991016057A1 (en) | 1990-04-18 | 1991-10-31 | University Of Utah | COLONIC-TARGETED ORAL DRUG-DOSAGE FORMS BASED ON CROSSLINKED HYDROGELS CONTAINING AZOBONDS AND EXHIBITING pH-DEPENDENT SWELLING |
| AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| DE733059T1 (de) | 1993-12-09 | 1997-08-28 | Univ Jefferson | Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen |
| WO1999029721A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| US7041814B1 (en) | 1998-02-18 | 2006-05-09 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics |
| JP2002510336A (ja) * | 1998-04-11 | 2002-04-02 | エレカッパ・ユウロテラピッチ・ソシエタ・ペル・アチオニ | 水溶性ケトプロフェン塩を含有する薬学的調製物及びその使用方法 |
| US7601685B2 (en) | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| JP2004520088A (ja) | 2000-08-15 | 2004-07-08 | サーモディックス，インコーポレイティド | 薬剤混和マトリックス |
| EP1351702B1 (en) | 2000-12-08 | 2015-03-04 | Bioprovar Corporation | Trem-1 splice variant for use in modifying immune responses |
| WO2002057413A2 (en) | 2001-01-18 | 2002-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta pkc |
| DE10118774A1 (de) | 2001-04-17 | 2002-10-31 | Jerini Ag | Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| JP2005506836A (ja) | 2001-08-23 | 2005-03-10 | アリゾナ・ボード・オブ・リージェンツ | 平滑筋治療用薬剤および方法 |
| US20030134810A1 (en) | 2001-10-09 | 2003-07-17 | Chris Springate | Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents |
| IL163575A0 (en) * | 2002-02-21 | 2005-12-18 | Univ Rockefeller | Compositions and method for regulation of calcium-dependent signalling in brain |
| US20040005686A1 (en) | 2002-03-07 | 2004-01-08 | Pharmacia Corporation | Crystalline structure of human MAPKAP kinase-2 |
| US20070026518A1 (en) | 2005-03-29 | 2007-02-01 | The Regents Of The University Of California | Controlling stem cell destiny with tunable matrices |
| US20030190364A1 (en) | 2002-04-01 | 2003-10-09 | Alyssa Panitch | Biological affinity based delivery systems |
| US7364870B2 (en) | 2002-08-02 | 2008-04-29 | Wyeth | MK2 interacting proteins |
| ZA200504898B (en) | 2002-12-20 | 2006-11-29 | Pharmacia Corp | Acyclic pyrazole compounds |
| DE602004001509T2 (de) | 2003-02-21 | 2007-02-15 | Arizona Board Of Regents, Tempe | Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung |
| IL156429A0 (en) * | 2003-06-12 | 2004-01-04 | Peptor Ltd | Cell permeable conjugates of peptides for inhibition of protein kinases |
| AU2004281838B2 (en) | 2003-10-17 | 2008-01-31 | Arizona Board Of Regents | Novel heat shock protein 20-related polypeptides and uses therefor |
| US20060141528A1 (en) | 2004-05-21 | 2006-06-29 | Aebersold Rudolf H | Compositions and methods for quantification of serum glycoproteins |
| AU2005332637B2 (en) | 2004-07-23 | 2011-04-07 | The Trustees Of The University Of Pennsylvania | Antimicrobial copolymers and uses thereof |
| US20060115453A1 (en) * | 2004-11-12 | 2006-06-01 | Yaffe Michael B | Methods and compositions for treating cellular proliferative diseases |
| US8008093B2 (en) | 2004-12-02 | 2011-08-30 | The University Of North Carolina At Chapel Hill | Inhibition of Hsp27 phosphorylation for the treatment of blistering disorders |
| US7767642B2 (en) | 2005-04-15 | 2010-08-03 | Arizona Biomedical Research Commission | Therapeutic peptides for the treatment of metastatic cancer |
| EP1948259B1 (en) | 2005-10-26 | 2017-03-22 | Genesis Technologies Limited | Acellular bioabsorbable tissue regeneration matrices produced by incubating acellular blood products |
| CA2626868A1 (en) | 2005-11-01 | 2007-05-10 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizo Na State University | Novel protein transduction domains and uses therefor |
| WO2007062060A2 (en) | 2005-11-22 | 2007-05-31 | Ted Reid | Methods and compositions using substance p to promote wound healing |
| EP2051727A4 (en) | 2006-07-12 | 2012-03-14 | Univ Arizona | METHOD FOR THE TREATMENT OF FIBROTIC DISEASES AND KELOIDS |
| AU2007342674B2 (en) * | 2007-01-10 | 2013-09-19 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| US20080293640A1 (en) * | 2007-01-10 | 2008-11-27 | Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| JP5703466B2 (ja) | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| WO2009123759A2 (en) | 2008-04-02 | 2009-10-08 | Moerae Matrix, Inc. | Therapeutic uses of biocompatible biogel compositions |
| CN102256613B (zh) | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| CA2744104C (en) | 2008-12-10 | 2017-07-18 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| US20130115256A1 (en) | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
| BR112013026313A8 (pt) | 2011-04-12 | 2018-01-30 | Moerae Matrix Inc | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular |
-
2008
- 2008-08-07 JP JP2010520314A patent/JP5703466B2/ja not_active Expired - Fee Related
- 2008-08-07 WO PCT/US2008/072525 patent/WO2009021137A2/en not_active Ceased
- 2008-08-07 EP EP20080797416 patent/EP2185698B1/en not_active Not-in-force
- 2008-08-07 ES ES08797416.8T patent/ES2547229T3/es active Active
- 2008-08-07 US US12/188,109 patent/US8741849B2/en not_active Expired - Fee Related
- 2008-08-07 DK DK08797416.8T patent/DK2185698T3/en active
-
2014
- 2014-04-22 US US14/258,418 patent/US9447158B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010535508A5 (https=) | ||
| ES2425083T3 (es) | Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II | |
| ES2342042T3 (es) | Derivados del acido indolil-3-glioxilico con valiosas propiedades terapeuticas. | |
| ES2367028T3 (es) | Composiciones sinérgicas con fk-228. | |
| CN102883736A (zh) | 用于促进血管生成的肽及其用途 | |
| JP2003521441A (ja) | 化学療法後の白血球生残率を増加させる方法 | |
| NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| US20060106049A1 (en) | Histone deacetylase inhibitors and methods of use | |
| AU2008335840A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4) | |
| US6693134B2 (en) | Bicyclic aromatic chemokine receptor ligands | |
| AU2008338594A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA) | |
| JP2012518602A (ja) | 複数の細胞活性化経路の阻害 | |
| CN114644687A (zh) | 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用 | |
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| WO2016071431A1 (en) | A combination for cancer therapy | |
| CN114364691B (zh) | 作为纤维化基质积累的抑制剂的肽 | |
| EP0944311B1 (en) | Method for antagonizing HEREGUlin or its receptor and use for the inhibition of cancer cells | |
| US20240325493A1 (en) | Regulator of tumor cell functions and uses thereof | |
| WO1998021956A9 (en) | Heregulin antagonists and methods for their use | |
| WO2013158959A1 (en) | Compositions and methods for treatment of graft-versus-host disease | |
| CN101642462B (zh) | 一种肿瘤抑制剂nrn1sr42 | |
| WO2024057793A1 (ja) | 癌転移を抑制するシトルリン化ペプチド | |
| RU2008125167A (ru) | Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные | |
| KR20020069392A (ko) | 인간의 페록시레독신 ｉｉ 안티센스 서열 및 이의 용도 | |
| JP4395901B2 (ja) | 新規遺伝子治療用薬剤 |